Dapagliflozin effective in treating type 1 diabetes
Type 1 diabetes is a worrying condition as ones immune system destroys insulin-making cells in the pancreas. Recent data published in PLOS One supports the preventive and protective role of SGLT2 inhibitors in cardiovascular disease (CVD) associated with type 1 diabetes.
The study provides experimental data for SGLT2i dapagliflozin's (DAPA) cardioprotective effect in T1D. Results showed that DAPA prevents cardiac inflammation, fibrosis, and intimal thickening. This suggests that SGLT2i may provide a novel therapeutic opportunity for hindering the development of CVD in type 1 diabetes, thereby improving the outcomes.
For more information check out the full story on the link below:
SGLT2 Inhibitor Dapagliflozin May Prevent Cardiovascular Complications In Type 1 Diabetes: Study
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.